Clinical trial
Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma
NCT00142428 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00142428 |
|---|---|
| Title | Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma |
| Official title | A Phase II Study of Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center Brigham and Women's Hospital Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | Cetuximab |
| Enrollment | 30 |
| Start date | Jan 1, 2005 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2008 |
| First posted | Sep 2, 2005 |
| Last update posted | Mar 18, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: